



1614
\$

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter David DAVIS

Serial No.: 09/890,989

Group No.: 1614

Filed: December 14, 2001

Examiner.: Misook Yu

For: COMBINATION FOR THE TREATMENT OF DISEASES INVOLVING
ANGIOGENESIS

Attorney Docket No.: U 013589-7

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the documents annexed hereto as
Annexes A, B and C, and listed on attached PTO Form 1449. Copies of the
documents are also annexed.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office, to **(708) 872-9306**

Date: January 14, 2005

Signature

CLIFFORD J. MASS

(type or print name of person certifying)

***WARNING:**


Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail"
mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label
thereon is an oversight that can be avoided by the exercise of reasonable care, requests for
waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed.
Reg. 56,439, at 56,442.

Annex A, Tozer et al, was published after the priority date of the present application and contains data showing the potentiating effect of combining Combretastatin A4 with a number of NOS inhibitors including L-NNA and L-NAME (see Annex A figure 6 and p 1630 col. 1).

Annex B, Davis et al, further illustrates that a wide range of NOS inhibitors are effective when used in combination with Combretastatin A4. See in particular figure 1 on page 1533 of Annex B.

Annex C contains data that has been submitted for publication by Wachsberger et al. In Annex C it is shown that the co-administration of the vascular tubulin binding agent ZD6126 and the NOS inhibitor L-NNA was able to overcome resistance to ZD6126 in U87 glioblastoma cells (see Annex C, page 10 last paragraph to page 11, first paragraph, page 15 last paragraph and table 1). In particular Table 1 in Annex C clearly illustrates the enhanced tumour necrosis in this model obtained by dosing ZD6126 together with L-NNA.

Respectfully submitted,



CLIFFORD J. MASS
LADAS & PARRY LLP
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.30,086(212)708-1890

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK
OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 013589-7**09/890,989**

APPLICANT

Peter David DAVIS

FILING DATE

GROUP

December 14,**1614**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AR	Annex A - Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues: Tozer, Prise, Wilson, Locke, Vojnovic, Stratford, Dennis, Chaplin: Cancer Research 59, 1626-1634, April 1, 1999
	AS	Annex B - Enhancement of Vascular Targeting by Inhibitors of Nitric Oxide Synthase: Davis, Tozer, Naylor, Thomson, Lewis, Hill: Int. J. Radiation Oncology Biol. Phys. Vol. 54, No. 5 pp. 1532-1536, 2002
	AT	Annex C - Effect of the tumor vascular damaging agent, ZD6126 on the radioresponse of U97 glioblastoma: Wachsberger, Burd, Marrero, Daskalakis, Ryan, McCue, Dicker:

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.